CAS Corporation

CAS, a division of the American Chemical Society, announced a collaboration with Novartis Biomedical Research to enhance reaction data accessibility and support AI-enabled research. Under the initiative, CAS will apply its data transformation services through CAS Intelligence Hub to organize and standardize Novartis' extensive collection of proprietary experimental reaction data, making it searchable alongside more than 160 million scientist-curated reactions from the CAS Content Collection. CAS will also work with Novartis to develop a customized discovery platform built on the CAS SciFinder architecture, designed to let Novartis researchers search, analyze, and cross-reference their enriched internal reaction data and CAS data simultaneously. Tim Wahlberg, Interim President of CAS, said the collaboration reflects the critical importance of a strong scientific data infrastructure alongside domain-specific technology and expertise for drug discovery workflows. The effort addresses the long-standing challenge of searching internal and external data together and lays the foundation for future CAS platform capabilities, including large language models and agentic AI.